The cash deal to acquire the PET radiopharmaceuticals CMO from Trilantic North America is expected to close in H1 2027.

The study by Choi et al 6 is of interest for a variety of reasons. Their radiomics model was able to predict clinical interpretation of cardiac FDG uptake patterns with good predictive accuracy. In ...

DUBLIN--(BUSINESS WIRE)--The "Positron Emission Tomography (PET) Scanners - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. The global market for Positron ...

The Canadian Urological Association (CUA) has published a multidisciplinary expert report offering Canadian consensus recommendations on prostate-specific membrane antigen (PSMA) positron emission ...

We surveyed oncologists who treat classic Hodgkin lymphoma (cHL) as part of the CONNECT study to understand the treatment decision‐making process, including the impact of positron emission ...

Broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron ...

The quantum entanglement of photons used in positron emission tomography (PET) scans has been shown to be surprisingly robust, opening prospects for developing quantum-enhanced PET schemes. Figure 1: ...

Niagara Falls, NY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT ...

Positron emission tomography (PET) has emerged as a pivotal imaging modality in neuro-oncology, enabling non-invasive characterisation of tumour metabolism, proliferative activity and molecular ...

Positron emission tomography (PET) has emerged as a pivotal imaging modality in the detection, staging and management of prostate cancer. By administering a radiotracer that selectively binds to ...

Magnetic resonance imaging and positron emission tomography offer diagnostic and prognostic value in pediatric focal epilepsy.